Entero Therapeutics, Inc.
ENTO
$0.3541
-$0.0241-6.37%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -198.43% | 24.84% | -110.25% | 236.77% | -2.88% |
| Total Depreciation and Amortization | -569.86% | -82.19% | 383.56% | 68.49% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6,600.88% | -43.44% | 1,575.14% | -2,715.84% | -91.56% |
| Change in Net Operating Assets | 183.07% | 304.08% | -86.70% | -46.55% | 114.10% |
| Cash from Operations | 95.01% | 44.51% | -24.96% | -31.68% | 38.50% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -15.70% | -6.21% | -1.30% | -- |
| Issuance of Common Stock | -100.00% | -68.77% | -58.77% | -4.38% | -40.98% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.73% | -71.18% | -64.75% | -4.74% | -21.10% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -148.47% | -114.38% | -234.31% | -139.90% | 242.60% |